Xilio director granted 5,000 stock options

Xilio Therapeutics director Xu Yuan received a grant of stock options as equity compensation.

Rhea-AI Filing Summary

Xilio Therapeutics director Xu Yuan received a grant of stock options as equity compensation. The award covers 5,000 options to buy common stock at an exercise price of $7.99 per share, expiring on June 10, 2036.

The options were granted on June 11, 2026 and will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting after the grant date, as long as Xu Yuan continues to serve the company through that vesting date. After this grant, the filing shows Xu Yuan holding 5,000 derivative securities (stock options).

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider Xu Yuan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	5,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 5,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Key Figures

Options granted: 5,000 options Exercise price: $7.99 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 5,000 options Stock Option (right to buy) granted June 11, 2026

Exercise price $7.99 per share Conversion or exercise price for the options

Expiration date June 10, 2036 Option expiration for the 5,000 stock options

Shares underlying options 5,000 shares Underlying common stock tied to the option grant

Post-transaction derivative holdings 5,000 options Total derivative securities following the grant

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 7.9900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest as to 100% of the shares underlying the option"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xu Yuan report for Xilio Therapeutics (XLO)?

Xu Yuan reported receiving a grant of 5,000 stock options for Xilio Therapeutics. These options allow the purchase of common stock at an exercise price of $7.99 per share as part of director equity compensation, not an open-market stock purchase or sale.

What are the key terms of Xu Yuan’s Xilio Therapeutics (XLO) stock option grant?

The grant covers 5,000 stock options with a $7.99 per share exercise price and an expiration date of June 10, 2036. The options represent the right to buy Xilio common stock in the future if the vesting conditions are met.

When do Xu Yuan’s Xilio Therapeutics (XLO) stock options vest?

The options vest as to 100% of the underlying 5,000 shares on the earlier of June 11, 2027 or Xilio’s next annual stockholder meeting after the grant date, provided Xu Yuan continues serving the company through that vesting date.

Does this Xilio Therapeutics (XLO) Form 4 show a stock purchase or sale by Xu Yuan?

The Form 4 reports a stock option grant, not a market trade. Xu Yuan acquired derivative securities (options) at a price of $0.00 per option, giving the right to buy common shares later at $7.99 per share if exercised.

How many Xilio Therapeutics (XLO) derivative securities does Xu Yuan hold after this grant?

After the reported transaction, Xu Yuan holds 5,000 derivative securities in the form of stock options. These options each relate to one share of Xilio common stock and reflect the position reported in this specific Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Yuan

(Last) (First) (Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.99	06/11/2026		A		5,000		(1)	06/10/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Christopher Frankenfield, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)